Vbr-bone

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Key Technology Research and Development Program of Shandong and 1 more

Animals1

Outcomes

Cellular senescence

downin mice1

1 study

Vbr-bone decreases cellular senescence in mice.
“In aged murine models, the vBR-Bone exhibits a rejuvenated restoration of bone bioactivity lost in aging, with reduced senescence, elevated remodeling, and improved stem cell functionality.”
Animalsbone
Development-based In Vivo Bioreactor Strategy for Challenging Senescent Bone Reconstruction
Advanced science (Weinheim, Baden-Wurttemberg, Germany)9 Mar 2026

Latest

1 in 12 months

Advanced Science9 Mar

Development-based In Vivo Bioreactor Strategy for Challenging Senescent Bone Reconstruction

Experiments in miceBones and joints

Paper

Vbr-bone

Outcomes

Latest

Development-based In Vivo Bioreactor Strategy for Challenging Senescent Bone Reconstruction

Related